Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $400.00 Price Target at HC Wainwright

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective raised by HC Wainwright from $395.00 to $400.00 in a research note issued to investors on Tuesday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other research analysts also recently issued reports on ALNY. Chardan Capital reaffirmed a buy rating and set a $225.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, May 3rd. Cantor Fitzgerald reaffirmed a neutral rating and issued a $165.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Wells Fargo & Company reduced their price objective on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an equal weight rating on the stock in a research note on Friday, February 16th. Royal Bank of Canada reaffirmed an outperform rating and issued a $235.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, Citigroup reduced their price target on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a buy rating on the stock in a research report on Friday, February 16th. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $216.19.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $154.33 on Tuesday. The stock has a fifty day moving average price of $149.41 and a two-hundred day moving average price of $165.02. The company has a market cap of $19.52 billion, a price-to-earnings ratio of -57.59 and a beta of 0.41. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. The firm’s quarterly revenue was up 54.8% on a year-over-year basis. During the same quarter last year, the company earned ($1.40) EPS. As a group, research analysts predict that Alnylam Pharmaceuticals will post -4.43 EPS for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC increased its stake in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares during the last quarter. Quent Capital LLC increased its position in shares of Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 123 shares during the last quarter. Anchor Investment Management LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $38,000. Robeco Institutional Asset Management B.V. boosted its position in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 12,513 shares during the last quarter. Finally, GAMMA Investing LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $52,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.